Voyager Therapeutics, Inc.
VYGRUS売上高
$40M
百万USD
営業利益
$-132M
百万USD
純利益
$-120M
百万USD
ROE
-61.1%
最新FY
EPS
$-2.04
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $7M | $-22M | - |
| FY2021 | Q2 | $1M | $-30M | - |
| FY2021 | Q3 | $1M | $-25M | $-0.67 |
| FY2021 | FY | $37M | $-71M | $-1.89 |
| FY2022 | Q1 | $1M | $-21M | $-0.56 |
| FY2022 | Q2 | $1M | $-19M | $-0.50 |
| FY2022 | Q3 | $41M | $18M | $0.45 |
| FY2022 | FY | $41M | $-46M | $-1.21 |
| FY2023 | Q1 | $150M | $124M | $2.94 |
| FY2023 | Q2 | $5M | $-22M | $-0.51 |
| FY2023 | Q3 | $5M | $-26M | $-0.59 |
| FY2023 | FY | $250M | $132M | $2.97 |
| FY2024 | Q1 | $20M | $-11M | $-0.20 |
| FY2024 | Q2 | $30M | $-10M | $-0.18 |
| FY2024 | Q3 | $25M | $-9M | $-0.16 |
| FY2024 | FY | $80M | $-65M | $-1.13 |
| FY2025 | Q1 | $6M | $-31M | $-0.53 |
| FY2025 | Q2 | $5M | $-33M | $-0.57 |
| FY2025 | Q3 | $13M | $-28M | $-0.47 |
| FY2025 | FY | $40M | $-120M | $-2.04 |
| FY2026 | Q1 | $3M | $-28M | $-0.47 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $8M | $104M | $171M | $37M | $41M | $250M | $80M | $40M |
| 営業利益 | $-41M | $-72M | $-91M | $-52M | $27M | $-74M | $-51M | $122M | $-83M | $-132M |
| 純利益 | $-40M | $-71M | $-88M | $-44M | $37M | $-71M | $-46M | $132M | $-65M | $-120M |
| 総資産 | $190M | $184M | $177M | $355M | $262M | $194M | $159M | $351M | $393M | $252M |
| 純資産 | - | - | - | - | - | - | - | - | - | - |
| 自己資本 | $136M | $134M | $46M | $100M | $154M | $95M | $59M | $236M | $300M | $196M |
| 営業CF | - | $-61M | $-16M | $49M | $-97M | $-54M | $-13M | $78M | $-15M | $-132M |
| EPS | - | - | - | - | $0.98 | $-1.89 | $-1.21 | $2.97 | $-1.13 | $-2.04 |
| BPS | $5.06 | $4.16 | $1.42 | $2.68 | $4.10 | $2.49 | $1.36 | $4.35 | $5.43 | $3.29 |
| ROE | -29.6% | -52.7% | -190.1% | -43.8% | 23.8% | -74.9% | -78.6% | 56.0% | -21.7% | -61.1% |